Nephrolithiasis-associated bone disease: Pathogenesis and treatment options

Kidney International

Volumn 79, Issue 4, 2011, Pages 393-403

  Sakhaee, Khashayar ^a,b   Maalouf, Naim M ^a,b   Kumar, Rajiv ^c,d   Pasch, Andreas ^c,d   Moe, Orson W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

bone disease; citrate; kidney stone; nephrolithiasis; thiazide

Indexed keywords

ADENYLATE CYCLASE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM OXALATE; CHLORTALIDONE; CITRATE POTASSIUM; CYTOKINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; POTASSIUM ALKALI; POTASSIUM CHLORIDE; POTASSIUM DERIVATIVE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE HISTOMORPHOMETRY; BONE METABOLISM; CALCIUM EXCRETION; CALCIUM OXALATE STONE; DENT DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HORMONE RELEASE; HUMAN; HYPERCALCIURIA; HYPERCALCIURIC NEPHROLITHIASIS; KIDNEY TUBULE ACIDOSIS; LOWE SYNDROME; MORPHOMETRICS; NEPHROLITHIASIS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; VERTEBRA FRACTURE;

EID: 79551543869     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.473     Document Type: Review

References (156)

1. Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63: 1817-1823.
2. Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol 2005; 173: 848-857.
3. Melton III LJ, Crowson CS, Khosla S et al. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 1998; 53: 459-464.
4. Lauderdale DS, Thisted RA, Wen M et al. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 2001; 16: 1893-1898.
5. Sakhaee K. Pharmacology of stone disease. Adv Chronic Kidney Dis 2009; 16: 30-38.
6. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001; 285: 785-795.
7. Alhava EM, Juuti M, Karjalainen P. Bone mineral density in patients with urolithiasis. A preliminary report. Scand J Urol Nephrol 1976; 10: 154-156.
8. Lawoyin S, Sismilich S, Browne R et al. Bone mineral content in patients with calcium urolithiasis. Metabolism 1979; 28: 1250-1254.
9. Fuss M, Gillet C, Simon J et al. Bone mineral content in idiopathic renal stone disease and in primary hyperparathyroidism. Eur Urol 1983; 9: 32-34.
10. Barkin J, Wilson DR, Manuel MA et al. Bone mineral content in idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 1985; 11: 19-24.
11. Fuss M, Pepersack T, Van Geel J et al. Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers. Calcif Tissue Int 1990; 46: 9-13.
12. Pacifici R, Rothstein M, Rifas L et al. Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1990; 71: 138-145.
13. Bataille P, Achard JM, Fournier A et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: 1193-1205.
14. Borghi L, Meschi T, Guerra A et al. Vertebral mineral content in diet-dependent and diet-independent hypercalciuria. J Urol 1991; 146: 1334-1338.
15. Pietschmann F, Breslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7: 1383-1388.
16. Jaeger P, Lippuner K, Casez JP et al. Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 1994; 9: 1525-1532.
17. Zanchetta JR, Rodriguez G, Negri AL et al. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron 1996; 73: 557-560.
18. Weisinger JR, Alonzo E, Bellorin-Font E et al. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996; 49: 244-250.
19. Ghazali A, Fuentes V, Desaint C et al. Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997; 82: 32-38.
20. Giannini S, Nobile M, Sartori L et al. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol 1998; 50: 94-100.
21. Trinchieri A, Nespoli R, Ostini F et al. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 1998; 159: 654-657.
22. Tasca A, Cacciola A, Ferrarese P et al. Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology 2002; 59: 865-869; discussion 9.
23. Misael da Silva AM, dos Reis LM, Pereira RC et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002; 57: 183-191.
24. Asplin JR, Bauer KA, Kinder J et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003; 63: 662-669.
25. Vezzoli G, Rubinacci A, Bianchin C et al. Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis 2003; 42: 1177-1183.
26. Caudarella R, Vescini F, Buffa A et al. Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol 2003; 16: 260-266.
27. Pasch A, Frey FJ, Eisenberger U et al. PTH and 1.25 vitamin D response to a low-calcium diet is associated with bone mineral density in renal stone formers. Nephrol Dial Transplant 2008; 23: 2563-2570.
28. Bordier P, Ryckewart A, Gueris J et al. On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med 1977; 63: 398-409.
29. Malluche HH, Tschoepe W, Ritz E et al. Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980; 50: 654-658.
30. De Vernejoul MC, Kuntz D, Miravet L et al. Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 1981; 33: 369-374.
31. Steiniche T, Mosekilde L, Christensen MS et al. A histomorphometric determination of iliac bone remodeling in patients with recurrent renal stone formation and idiopathic hypercalciuria. APMIS 1989; 97: 309-316.
32. Heilberg IP, Martini LA, Szejnfeld VL et al. Bone disease in calcium stone forming patients. Clin Nephrol 1994; 42: 175-182.
33. Bataille P, Hardy P, Marie A. Decreased bone formation in idiopathic hypercalciuric calcium stone formers explains reduced bone density (abstract). J Bone Miner Res 1995; 10(Suppl 1): 401.
34. Heller HJ, Zerwekh JE, Gottschalk FA et al. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 2007; 71: 808-815.
35. Preminger GM, Sakhaee K, Pak CY. Hypercalciuria and altered intestinal calcium absorption occurring independently of vitamin D in incomplete distal renal tubular acidosis. Metabolism 1987; 36: 176-179.
36. Weger M, Deutschmann H, Weger W et al. Incomplete renal tubular acidosis in 'primary' osteoporosis. Osteoporos Int 1999; 10: 325-329.
37. Granberg PO, Lagergren C, Theve NO. Renal function studies in medullary sponge kidney. Scand J Urol Nephrol 1971; 5: 177-180.
38. Higashihara E, Nutahara K, Tago K et al. Medullary sponge kidney and renal acidification defect. Kidney Int 1984; 25: 453-459.
39. Fabris A, Bernich P, Abaterusso C et al. Bone disease in medullary sponge kidney and effect of potassium citrate treatment. Clin J Am Soc Nephrol 2009; 4: 1974-1979.
40. Borghi L, Schianchi T, Meschi T et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346: 77-84.
41. Hess B, Ackermann D, Essig M et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 1995; 80: 1916-1921.
42. Breslau NA, Brinkley L, Hill KD et al. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66: 140-146.
43. Buck AC, Sampson WF, Lote CJ et al. The influence of renal prostaglandins on glomerular filtration rate (GFR) and calcium excretion in urolithiasis. Br J Urol 1981; 53: 485-491.
44. Sutton RA, Wong NL, Dirks JH. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 1979; 15: 520-533.
45. Frings-Meuthen P, Baecker N, Heer M. Low-grade metabolic acidosis may be the cause of sodium chloride-induced exaggerated bone resorption. J Bone Miner Res 2008; 23: 517-524.
46. Frick KK, Jiang L, Bushinsky DA. Acute metabolic acidosis inhibits the induction of osteoblastic egr-1 and type 1 collagen. Am J Physiol 1997; 272(5 Part 1): C1450-C1456.
47. Frick KK, Bushinsky DA. Chronic metabolic acidosis reversibly inhibits extracellular matrix gene expression in mouse osteoblasts. Am J Physiol 1998; 275(5 Part 2): F840-F847.
48. Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol 1992; 262(3 Part 2): F442-F448.
49. Frick KK, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. J Bone Miner Res 2003; 18: 1317-1325.
50. Frick KK, Bushinsky DA. In vitro metabolic and respiratory acidosis selectively inhibit osteoblastic matrix gene expression. Am J Physiol 1999; 277(5 Part 2): F750-F755.
51. Krieger NS, Frick KK, LaPlante Strutz K et al. Regulation of COX-2 mediates acid-induced bone calcium efflux in vitro. J Bone Miner Res 2007; 22: 907-917.
52. Frick KK, LaPlante K, Bushinsky DA. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. Am J Physiol Renal Physiol 2005; 289: F1005-F1011.
53. Reed BY, Heller HJ, Gitomer WL et al. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab 1999; 84: 3907-3913.
54. Reed BY, Gitomer WL, Heller HJ et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 2002; 87: 1476-1485.
55. Ichikawa S, Koller DL, Curry LR et al. Association of adenylate cyclase 10 (ADCY10) polymorphisms and bone mineral density in healthy adults. Calcif Tissue Int 2009; 84: 97-102.
56. Geng W, Hill K, Zerwekh JE et al. Inhibition of osteoclast formation and function by bicarbonate: role of soluble adenylyl cyclase. J Cell Physiol 2009; 220: 332-340.
57. Thorleifsson G, Holm H, Edvardsson V et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009; 41: 926-930.
58. Thakker RV. Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 2000; 57: 787-793.
59. Hoopes Jr RR, Shrimpton AE, Knohl SJ et al. Dent disease with mutations in OCRL1. Am J Hum Genet 2005; 76: 260-267.
60. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-449.
61. Prie D, Huart V, Bakouh N et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347: 983-991.
62. Virkki LV, Forster IC, Hernando N et al. Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa. J Bone Miner Res 2003; 18: 2135-2141.
63. Lapointe JY, Tessier J, Paquette Y et al. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 2006; 69: 2261-2267.
64. Heilberg IP, Martini LA, Teixeira SH et al. Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 1998; 79: 430-437.
65. Da Silva A, Dos Ries L, Periera R (eds) Bone histomorphometric and bone mineral content in idiopathic hypercalciuria patients (abstract). XIIth International Congress of Nephrology 1993, Jerusalem, Israel.
66. Kaplan RA, Haussler MR, Deftos LJ et al. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 1977; 59: 756-760.
67. Broadus AE, Insogna KL, Lang R et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984; 311: 73-80.
68. Coe FL, Favus MJ, Crockett T et al. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982; 72: 25-32.
69. Insogna KL, Broadus AE, Dreyer BE et al. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 1985; 61: 490-495.
70. Favus MJ, Karnauskas AJ, Parks JH et al. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89: 4937-4943.
71. Raisz LG, Kream BE, Smith MD et al. Comparison of the effects of vitamin D metabolites on collagen synthesis and resportion of fetal rat bone in organ culture. Calcif Tissue Int 1980; 32: 135-138.
72. Mundy GR, Boyce B, Hughes D et al. The effects of cytokines and growth factors on osteoblastic cells. Bone 1995; 17(2 Suppl): 71S-75S.
73. Gomes SA, dos Reis LM, Noronha IL et al. RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol 2008; 3: 1446-1452.
74. Vega D, Maalouf NM, Sakhaee K. Clinical review. J Clin Endocrinol Metab 2007; 92: 4514-4521.
75. Siggelkow H, Eidner T, Lehmann G et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 2003; 18: 529-538.
76. Brocks P, Dahl C, Wolf H et al. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1981; 2: 124-125.
77. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982; 128: 903-907.
78. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 1984; 215: 383-389.
79. Ettinger B, Citron JT, Livermore B et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988; 139: 679-684.
80. Ohkawa M, Tokunaga S, Nakashima T et al. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 1992; 69: 571-576.
81. Borghi L, Meschi T, Guerra A et al. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993; 22(Suppl 6): S78-S86.
82. Yendt ER, Guay GF, Garcia DA. The use of thiazides in the prevention of renal calculi. Can Med Assoc J 1970; 102: 614-620.
83. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977; 87: 404-410.
84. Yendt ER, Cohanim M. Thiazides and calcium urolithiasis. Can Med Assoc J 1978; 118: 755-758.
85. Maschio G, Tessitore N, D'Angelo A et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. Am J Med 1981; 71: 623-626.
86. Backman U, Danielson BG, Johansson G et al. Effects of therapy with bendroflumethiazide in patients with recurrent renal calcium stones. Br J Urol 1979; 51: 175-180.
87. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kidney Int 1978; 13: 397-409.
88. Barcelo P, Wuhl O, Servitge E et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993; 150: 1761-1764.
89. Ettinger B, Pak CY, Citron JT et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997; 158: 2069-2073.
90. Hofbauer J, Hobarth K, Szabo N et al. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis - a prospective randomized study. Br J Urol 1994; 73: 362-365.
91. Soygur T, Akbay A, Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol 2002; 16: 149-152.
92. Kang DE, Maloney MM, Haleblian GE et al. Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. J Urol 2007; 177: 1785-1788; discussion 8-9.
93. Pak CY, Fuller C, Sakhaee K et al. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985; 134: 11-19.
94. Whalley NA, Meyers AM, Martins M et al. Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. Br J Urol 1996; 78: 10-14.
95. Preminger GM, Sakhaee K, Skurla C et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134: 20-23.
96. Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant 2006; 21: 361-369.
97. Sakhaee K, Nicar M, Hill K et al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24: 348-352.
98. Lemann Jr J, Gray RW, Pleuss JA. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int 1989; 35: 688-695.
99. Sebastian A, Harris ST, Ottaway JH et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 1994; 330: 1776-1781.
100. Sakhaee K, Maalouf NM, Abrams SA et al. Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 3528-3533.
101. Dawson-Hughes B, Harris SS, Palermo NJ et al. Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women. J Clin Endocrinol Metab 2009; 94: 96-102.
102. Maurer M, Riesen W, Muser J et al. Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans. Am J Physiol Renal Physiol 2003; 284: F32-F40.
103. Lutz J. Calcium balance and acid-base status of women as affected by increased protein intake and by sodium bicarbonate ingestion. Am J Clin Nutr 1984; 39: 281-288.
104. Buclin T, Cosma M, Appenzeller M et al. Diet acids and alkalis influence calcium retention in bone. Osteoporos Int 2001; 12: 493-499.
105. Sellmeyer DE, Schloetter M, Sebastian A. Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab 2002; 87: 2008-2012.
106. Jehle S, Zanetti A, Muser J et al. Partial neutralization of the acidogenic Western diet with potassium citrate increases bone mass in postmenopausal women with osteopenia. J Am Soc Nephrol 2006; 17: 3213-3222.
107. Macdonald HM, Black AJ, Aucott L et al. Effect of potassium citrate supplementation or increased fruit and vegetable intake on bone metabolism in healthy postmenopausal women: a randomized controlled trial. Am J Clin Nutr 2008; 88: 465-474.
108. Pak CY, Peterson RD, Poindexter J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J Urol 2002; 168: 31-34.
109. Vescini F, Buffa A, La Manna G et al. Long-term potassium citrate therapy and bone mineral density in idiopathic calcium stone formers. J Endocrinol Invest 2005; 28: 218-222.
110. Frassetto L, Morris Jr RC, Sebastian A. Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 831-834.
111. Marangella M, Di Stefano M, Casalis S et al. Effects of potassium citrate supplementation on bone metabolism. Calcif Tissue Int 2004; 74: 330-335.
112. Zhou H, Choong P, McCarthy R et al. In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res 1994; 9: 1489-1499.
113. Amanzadeh J, Gitomer WL, Zerwekh JE et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int 2003; 64: 2142-2149.
114. Zerwekh JE, Zou L, Pak CY et al. Biochemical and histological assessment of alkali therapy during high animal protein intake in the rat. Bone 2009; 45: 1004-1009.
115. LaCroix AZ, Wienpahl J, White LR et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322: 286-290.
116. Cauley JA, Cummings SR, Seeley DG et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118: 666-673.
117. Nguyen TV, Eisman JA, Kelly PJ et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996; 144: 255-263.
118. Feskanich D, Willett WC, Stampfer MJ et al. A prospective study of thiazide use and fractures in women. Osteoporos Int 1997; 7: 79-84.
119. Rashiq S, Logan RF. Role of drugs in fractures of the femoral neck. Br Med J (Clin Res Ed) 1986; 292: 861-863.
120. Ray WA, Griffin MR, Downey W et al. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989; 1: 687-690.
121. Felson DT, Sloutskis D, Anderson JJ et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265: 370-373.
122. Herings RM, Stricker BH, de Boer A et al. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996; 49: 115-119.
123. Grisso JA, Kelsey JL, O'Brien LA et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997; 145: 786-793.
124. Wasnich RD, Benfante RJ, Yano K et al. Thiazide effect on the mineral content of bone. N Engl J Med 1983; 309: 344-347.
125. Wasnich R, Davis J, Ross P et al. Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 1990; 301: 1303-1305.
126. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol 1994; 139: 1107-1115.
127. Bauer DC, Browner WS, Cauley JA et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118: 657-665.
128. Dawson-Hughes B, Harris S. Thiazides and seasonal bone change in healthy postmenopausal women. Bone Miner 1993; 21: 41-51.
129. Glynn NW, Meilahn EN, Charron M et al. Determinants of bone mineral density in older men. J Bone Miner Res 1995; 10: 1769-1777.
130. Wasnich RD, Davis JW, He YF et al. A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women. Osteoporos Int 1995; 5: 247-251.
131. Transbol I, Christensen MS, Jensen GF et al. Thiazide for the postponement of postmenopausal bone loss. Metabolism 1982; 31: 383-386.
132. Bolland MJ, Ames RW, Horne AM et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 2007; 18: 479-486.
133. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109: 362-370.
134. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999; 130: 658-660.
135. Sakhaee K, Nicar MJ, Glass K et al. Postmenopausal osteoporosis as a manifestation of renal hypercalciuria with secondary hyperparathyroidism. J Clin Endocrinol Metab 1985; 61: 368-373.
136. Pak CY, Heller HJ, Pearle MS et al. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 2003; 169: 465-469.
137. Rico H, Revilla M, Villa LF et al. A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Miner Electrolyte Metab 1993; 19: 337-342.
138. Steiniche T, Mosekilde L, Christensen MS et al. Histomorphometric analysis of bone in idiopathic hypercalciuria before and after treatment with thiazide. APMIS 1989; 97: 302-308.
139. Ott SM, LaCroix AZ, Scholes D et al. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 2008; 19: 1315-1322.
140. Barilla DE, Tolentino R, Kaplan RA et al. Selective effects of thiazide on intestinal absorption of calcium and adsorptive and renal hypercalciurias. Metabolism 1978; 27: 125-131.
141. Aubin R, Menard P, Lajeunesse D. Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int 1996; 50: 1476-1482.
142. Lajeunesse D, Delalandre A, Guggino SE. Thiazide diuretics affect osteocalcin production in human osteoblasts at the transcription level without affecting vitamin D3 receptors. J Bone Miner Res 2000; 15: 894-901.
143. Barry EL, Gesek FA, Kaplan MR et al. Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol 1997; 272(1 Part 1): C109-C116.
144. Lalande A, Roux S, Denne MA et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res 2001; 16: 361-370.
145. Lau KH, Song XD, Ochi M et al. Mitogenic action of hydrochlorothiazide on human osteoblasts in vitro: requirement for platelet-derived growth factor. Calcif Tissue Int 1996; 59: 505-510.
146. Hall TJ, Schaueblin M. Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro. Calcif Tissue Int 1994; 55: 266-268.
147. Broulik PD, Pacovsky V. Hydrochlorothiazide inhibits parathormone- stimulated increase in plasma tartrate-resistant acid phosphatase in mice. Calcif Tissue Int 1991; 49: 51-52.
148. Bushinsky DA, Neumann KJ, Asplin J et al. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999; 55: 234-243.
149. Weisinger JR, Alonzo E, Machado C et al. Role of bones in the physiopathology of idiopathic hypercalciuria: effect of amino-bisphos-phonate alendronate. Medicina (B Aires) 1997; 57(Suppl 1): 45-48.
150. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010; 362: 1825-1827.
151. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
152. Miller PD, Bilezikian JP, Diaz-Curiel M et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007; 92: 3535-3541.
153. Taylor WH. Renal calculi and self-medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515-522.
154. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-683.
155. Berlin T, Holmberg I, Bjorkhem I. High circulating levels of 25-hydroxyvitamin D3 in renal stone formers with hyperabsorptive hypercalciuria. Scand J Clin Lab Invest 1986; 46: 367-374.
156. Netelenbos JC, Jongen MJ, van der Vijgh WJ et al. Vitamin D status in urinary calcium stone formation. Arch Intern Med 1985; 145: 681-684.